Clinical

A phase 2b trial found vixarelimab rapidly reduced itch and lesion burden in prurigo nodularis, with sustained benefit and a favorable safety profile.

Top pieces from 2025 spanned outbreaks, an FDA drug approval, and the impact of NIH grant terminations.

The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space.

Panelists discuss how the economic toll of poor LDL-C control demands workplace and systemwide prevention strategies.

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options.

Experts at SABCS highlighted the aggressive nature of breast cancer in young women, emphasizing tailored management and support strategies.

The FDA approved subcutaneous amivantamab with recombinant human hyaluronidase for EGFR-mutated NSCLC based on the phase 3 PALOMA-3 trial.

Leaders of OneOncology share how the managed services organization empowers independent oncology practices through advanced technology, clinical trials, and value-based care, enhancing patient-focused cancer treatment.

A study using Mendelian randomization found higher BMI and IBD have causal links to hidradenitis suppurativa risk.

A novel phase 1 trial explores the safety and efficacy of targeted radiotherapy for leptomeningeal metastases in breast cancer patients.

Marco del Riccio, MD, explains that the Flunomics report helped to identify gaps in US vaccine coverage and influenza surveillance during the 2024-2025 season.

Sustained long-term safety data for tildrakizumab strengthens the positioning of IL-23 inhibitors as a preferred choice, especially for patients with comorbidities or a history of infection, and suggests their potential use in combination therapies for psoriatic arthritis.

Zachary Contreras of Sharp Health Plan highlighted strategies discussed at AMCP Nexus for improving timely access to Monoclonal Migraine Receptor (MMR) therapy through updated coverage pathways, specialist input, and real-time benefit checks.

Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.

Zachary Contreras highlighted strategies discussed at AMCP Nexus for improving timely access to monoclonal migraine receptor (MMR) therapy through updated coverage pathways, specialist input, and real-time benefit checks.

Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.

Today, the FDA issued new guidance allowing de-identified real-world evidence in certain medical device applications, removing a barrier to using large data sources.

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated strong safety in patients with leptomeningeal metastases.

COVID-19 vaccination during pregnancy lowers hospitalization and preterm birth risks, providing key guidance for maternal care strategies.

Our top breast cancer stories in 2025 covered FDA approvals, new and failed therapies, screening gaps, and policy factors shaping treatment access and outcomes.

Linvoseltamab shows promise as a first-line therapy for multiple myeloma, offering high response rates and a simplified treatment approach.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

Top articles in 2025 covered advancements in acute myeloid leukemia treatments, including allogeneic CAR T-cell therapy.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.